Reckitt Benckiser Group (LON:RB) Given a GBX 7,400 Price Target by Berenberg Bank Analysts

Reckitt Benckiser Group (LON:RB – Get Rating) has been given a GBX 7,400 ($90.30) price target by equities researchers at Berenberg Bank in a research report issued to clients and investors on Thursday, Borsen Zeitung reports.

A number of other analysts also recently weighed in on the company. The Goldman Sachs Group set a GBX 6,400 ($78.10) price target on Reckitt Benckiser Group in a report on Thursday. Jefferies Financial Group set a GBX 5,620 ($68.58) price target on Reckitt Benckiser Group in a report on Tuesday, November 1st. UBS Group set a GBX 7,500 ($91.52) price target on Reckitt Benckiser Group in a report on Friday, January 13th. Deutsche Bank Aktiengesellschaft set a GBX 6,500 ($79.32) price target on Reckitt Benckiser Group in a report on Friday, December 16th. Finally, Sanford C. Bernstein set a GBX 6,100 ($74.44) target price on Reckitt Benckiser Group in a research note on Monday, January 9th.

Reckitt Benckiser Group Price Performance

The company has a current ratio of 0.77, a quick ratio of 0.53 and a debt-to-equity ratio of 116.01. Reckitt Benckiser Group has a 1-year low of GBX 5,782 ($70.56) and a 1-year high of GBX 8,020 ($97.86). The firm has a market capitalization of £48.36 billion and a PE ratio of 40.79.

Reckitt Benckiser Group Company Profile

(Get Rating)

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.